Idiopathic pneumonia syndrome (IPS) is a critical complication following allogeneic hematopoietic SCT (HSCT); however, few reports have analyzed the risk factors for IPS in children. A total of 210 consecutive pediatric patients, including 131 boys and 79 girls, with various hematologic malignancies, aplastic anemia or solid tumors who underwent allogeneic HSCT were analyzed to clarify the incidence and risk factors for IPS. Patient and transplantation characteristics after allogeneic HSCT were compared between patients with and without IPS. Cumulative incidence rates of IPS 120 days after allogeneic HSCT were 6.7% (14/210). Of 14 patients with IPS, 11 (78.6%) died after developing IPS. The presence of prior HSCT was more frequent in patients with IPS (IPS group) than in those without IPS (non-IPS group; 35.7 vs 12.8%, respectively, P ¼ 0.018). The IPS group contained more patients with acute GVHD (grade II-IV) than the non-IPS group (50.0 vs 18.9%, respectively, P ¼ 0.006). The association of these two factors with IPS was further confirmed by multivariate analysis. We should be aware of these risk factors in patients who have undergone allogeneic HSCT.
INTRODUCTION

Idiopathic pneumonia syndrome (IPS) is a critical complication following allogeneic hematopoietic SCT (HSCT)
. IPS was previously defined as the presence of widespread alveolar injury in the absence of active lower respiratory tract infection. 1 Over the years, this definition has been adopted into clinical practice and has been useful in guiding medical management in afflicted patients. [2] [3] [4] [5] [6] [7] [8] However, the outcomes of patients diagnosed with IPS remain poor; mortality rates are high and time to death following diagnosis is short. 9, 10 Therefore, an improved understanding of the clinical spectrum and mechanisms responsible for IPS are essential for physicians to make progress in the treatment and prevention of this clinical condition. Nevertheless, few reports have analyzed the risk profile of IPS in children. Our aim was to clarify the incidence and outcomes of IPS, and identify the risk factors for IPS in pediatric patients who underwent allogeneic HSCT.
PATIENTS AND METHODS Patients
A total of 210 pediatric patients who underwent allogeneic HSCT at Hokkaido University Hospital between February 1988 and March 2007, and at Sapporo Hokuyu Hospital between April 2007 and October 2012 were enrolled in this study. The age at HSCT ranged from 0 to 21 years old (median, 7 years). Sixty-nine (33%) patients had ALL, 38 (18%) had AML, 29 (14%) had aplastic anemia, 12 (6%) had neuroblastoma, 10 (5%) had juvenile myelomonocytic leukemia, 8 (4%) had myelodysplastic syndrome (MDS), 6 (3%) had non-Hodgkin lymphoma, 6 (3%) had CML, 6 (3%) had Wiskott-Aldrich syndrome, 5 (2%) had Hurler disease, 3 (1%) had SCID, 3 (1%) had Kostmann syndrome, 2 (1%) had chronic granulomatous disease, 2 (1%) had hepatoblastoma and 11 (5%) had various other diseases. The donors of HSCT were HLA-matched siblings in 76 cases, one or two Ag HLA-mismatched siblings in 6 cases, HLA-matched or HLA-mismatched parents in 15 cases, HLA-matched, unrelated donors in 50 cases, single-Ag HLA-mismatched, unrelated donors in 56 cases, and two Ag HLA-mismatched, unrelated donors in 7 cases. All patients had a normal pulmonary evaluation before HSCT.
The cumulative incidence of IPS until 120 days after HSCT was evaluated in this study. Patient and transplantation characteristics after allogeneic HSCT, such as age, sex, underlying disease, disease status, prior transplantation, types of HSCT, stem cell source, intensity of the conditioning regimen, components of the conditioning regimen, HLA compatibility, presence of acute GVHD, GVHD prophylaxis and the presence of CMV antigenemia were compared between patients with and without IPS. Data were analyzed as of 1 April 2013.
Informed consent was obtained from the patients or their parents according to the guidelines based on the tenets of the revised Helsinki protocol. The Institutional Review Board of Sapporo Hokuyu Hospital approved this project.
Definition of IPS
In this study, we retrospectively identified patients in whom IPS developed within the first 120 days of transplantation by examining computerized records of radiological examinations and chart reviews. IPS was defined as the presence of multilobar infiltrates by chest X-rays or computed tomography scans and the signs of pneumonia with abnormal pulmonary physiology, including the need for supplemental oxygenation with declining oximetry values. Patients with apparent pulmonary infection who responded quickly to anti-microbial agents were not categorized as having IPS. Patients with invasive fungal infection were excluded according to the standardized definitions from the European Organization for Research and Treatment of Cancer /Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Disease Mycosis study group criteria. 11 Patients with the signs and symptoms of fluid overload were not classified as having IPS if they responded to diuretic therapy. Lung biopsy and/or bronchoalveolar lavage for the identification of active lower respiratory infection were not performed because the procedures were too invasive and hazardous for children following HSCT. Autopsy was not performed as informed consent could not be obtained from parents.
Evaluation and diagnosis of acute GVHD GVHD grading was performed with an adjustment for comorbidity. 12 Grade II indicated stage 3 skin disease, or adjusted stage I liver or gut disease; and grade IV indicated death with uncontrolled GVHD as a major contributing cause. GVHD was treated with 1-2 mg/kg/day prednisolone equivalents and the resumption of full-dose CsA or tacrolimus (FK506) administration, if applicable. The initial dose of corticosteroids and tapering schedule of immunosuppressive medications were modified at the discretion of the attending physicians according to the presence or absence of malignant cells and the severity of GVHD. Acute GVHD was analyzed as a timedependent variable. Only acute GVHD diagnosed before IPS was considered as the factor for analysis.
Infection prophylaxis and diagnostic approach in patients with respiratory problems Until neutrophil engraftment, which was defined as an ANC of 40.5 Â 10 9 /L for 3 consecutive days, patients were housed in high-efficiency particulate air-filtered isolation rooms and provided with low microbial diets. Patients routinely received acyclovir (600 mg/m 2 p.o. four times daily) from day À 7 to þ 35 of HSCT. Anti-CMV high-titer Ig was infused weekly from day À 6 to þ 90, and i.v. G-CSF was administered from day þ 5 until neutrophil engraftment. The administration of trimethoprim sulfamethoxazole or inhaled pentamidine was used before day 0 of HSCT and after engraftment to prevent Pneumocystis jirovecii pneumonia. Peripheral blood was obtained weekly from engraftment to discharge to test for CMV antigenemia. Patients received pre-emptive therapy with ganciclovir or foscarnet when the test became positive.
Between February 1988 and March 2005, oral amphotericin B 100 mg/ kg/day was used for prophylaxis of fungal infection from the beginning of the conditioning regimen until the date of discharge (n ¼ 131). Between April 2005 and October 2012, i.v. micafungin 1 mg/kg/day was introduced as a prophylactic agent for fungal infection from the beginning of the conditioning regimen until neutrophil recovery, and thereafter by oral fluconazole 10 mg/kg/d until the date of discharge (n ¼ 79).
Patients with fever during neutropenia were treated with broadspectrum antibiotics after taking blood cultures. Patients with persistent fever following the administration of antibiotics were treated with other antibiotics as clinically indicated.
Statistical analysis
A w 2 -test or Mann-Whitney U-test was used to compare patients with or without IPS. Risk factors for developing IPS were evaluated by univariate and multivariate analysis using the Cox regression model. A multivariate model was constructed with the forward stepwise method using threshold P-values of 0.10 for removal or additions to the model. Values of Po0.05 were considered significant. Measures of association were expressed as hazard ratios with a 95% confidence interval. All statistical analyses were performed with Easy R (EZR) (Saitama Medical Center, Jichi Medical University), which is a graphical user interface for R (The R Foundation for Statistical Computing). More precisely, it is a modified version of the R commander designed to add statistical functions frequently used in biostatistics. 13 
RESULTS
Incidence of IPS
Fourteen patients fulfilled the definition of IPS described above. The cumulative incidence rate of IPS at 120 days after allogeneic HSCT was 6.7%. The profiles of 14 patients with IPS were shown in Table 1 . The onset of IPS ranged from 9 to 112 days after HSCT, with a median day of 58. Of these 14 patients, 5 (35.7%) had a prior history of HSCT. Seven of the 14 patients (50%) showed acute GVHD grade II-IV, and 6 (86%) of them developed acute GVHD before the onset of IPS. As seen in Table 1 , six cases with IPS were positive for CMV antigenemia. In four of the six cases, the antigenemia was detected in advance of the onset of IPS; however, CMV antigenemia had become negative by pre-emptive therapy for CMV at the onset of IPS in all cases. On the other hand, in the remaining two cases, CMV antigenemia became positive after improving IPS episode. After all, there is no case in which the CMV antigenemia was positive at the onset of IPS, thus we diagnosed all six cases as IPS instead of CMV pneumonia.
Comparison of variables between patients with and without IPS A comparison of variables between patients with IPS (IPS group) and without IPS (non-IPS group) was summarized in Table 2 . No significant differences in age, sex, underlying diseases or disease status were observed between these groups. Patients with prior HSCT were more frequent in the IPS group than in the non-IPS (Table 3) . No significant differences in the type of HSCT, stem cell source, intensity of the conditioning regimen, ingredients of the conditioning regimen, HLA compatibility, GVHD prophylaxis and the presence of CMV antigenemia were observed between the IPS group and non-IPS group.
Outcomes after IPS As summarized in Table 1 , of 14 patients with IPS, 11 patients (78.6%) died after developing this clinical condition. The time from the onset of IPS to death ranged from 0 to 183 days, with a median of 9 days. Six patients died from respiratory failure following IPS, two from acute renal failure, one from pulmonary hemorrhage, one from septic shock (Staphylococcus epidermidis) and one from intracranial hemorrhage. Among the 14 patients with IPS, 12 patients were treated with high-dose corticosteroid therapy, and mechanical ventilation was initiated for respiratory failure in nine patients. Patients with IPS in whom mechanical ventilation was initiated had 100% (9/9) mortality. The mortality rate of IPS patients not receiving mechanical ventilation was 40% (2/5) .
DISCUSSION
This study demonstrated that the presence of prior HSCT and acute GVHD of grade II-IV were extracted as the risk factors for IPS in pediatric patients after allogeneic HSCT. In adults, IPS typically occurred early after HSCT, with primary risk factors including older age, primary diagnosis of acute leukemia or MDS, use of TBI, and severe acute GVHD. [2] [3] [4] [5] [6] [7] [8] 10 However, few reports have analyzed the risk factors for IPS in pediatric HSCT recipients. [14] [15] [16] [17] In this regard, the present study provides valuable information on pediatric HSCT. The cumulative incidence of IPS at 120 days after conventional HSCT in the present study (6.7%) was similar to previously reported incidence rates using a similar definition of the syndrome and comparable diagnostic procedures. 10, 18, 19 This result indicates that IPS still leads to transplantation-related morbidity and mortality in spite of advances in diagnostic methods for opportunistic infections and improvements in supportive care.
IPS is reported to be the consequence of non-infectious lung injury after HSCT caused by the toxic effects of conditioning, immunological cell-mediated injury, inflammatory cytokines, floraderived lipopolysaccharides and also possibly occult pulmonary infections; 19, 20 however, the precise mechanism remains unclear. We found that acute GVHD grade II-IV was a risk factor for IPS. This result was consistent with previous reports. 3, [5] [6] [7] [8] 10, 18 In addition, acute GVHD grade II-IV was observed in 7 of 14 cases of IPS, and acute GVHD was ahead of IPS in most cases (6/7) in our cohort. These findings suggest immune-mediated lung injury may contribute to the development of IPS, and the lung may be a target organ of acute GVHD.
Regimen-related pulmonary toxicity is thought to be an important contributing factor to the development of IPS after HSCT. The inclusion of TBI in the conditioning regimen and radiation dose delivered to the lung have been identified as risk factors for IPS in adult patients. 4, 7, 21, 22 However, the use of TBI was not identified as a risk factor for IPS in our study. Previous reports on IPS in pediatric HSCT recipients have revealed that the TBIcontaining regimen was not a risk factor for IPS. 14, 17 If these reports, including our results, are taken into consideration, the Risk factor analysis of IPS in children H Sano et al influence of TBI on the onset of IPS may be smaller in pediatric HSCT recipients than in adult recipients. We identified prior HSCT as a risk factor for IPS in this study. There have been no reports similar to our result so far. It may be considered that the lung had been damaged by the toxicity of the conditioning regimen or immunological cell-mediated injury, such as GVHD, in the prior HSCT, which led to vulnerability to IPS. Among the patients undergoing prior HSCT, the frequency of acute GVHD (grade II-IV) in the previous HSCT was higher in the IPS group (2/5) than in the non-IPS group (2/25; 40 vs 8%, respectively, P ¼ 0.054). Although this difference was NS, apparently because of low number of analyzed patients, this result suggests that repeated acute GVHD is involved in the accumulation of pulmonary damage, giving rise to vulnerability to IPS. Further validation of this is recommended in the future.
The mortality rate of children with IPS was 79% (11/14) in the present study. In the previous reports (refs 14, 16, 17) , it was 73% (8/11), 53% (11/20) and 47% (14/30), respectively. Although the mortality rate in our study seemed higher than those in the previous reports, the difference was NS (P ¼ 0.13). There were no major differences in the treatment for IPS between those in the previous reports and our report. In each report, patients were treated with high-dose systemic corticosteroid and supportive care, including oxygen supplement and/or mechanical ventilation, with exception of five refractory patients in ref. 14 This study has several limitations inherent in the diagnosis, outcome and patient population. First, it was difficult to exactly determine the total number of patients with pulmonary signs or radiographic infiltrates because of the retrospective nature of the study. It is possible that IPS may have been missed in some patients because of mild symptoms or because the patients were too ill to undergo sufficient diagnostic procedures. For these reasons, the incidence of IPS may have been underestimated. Second, we did not perform invasive inspections, such as bronchoalveolar lavage collection, to exclude active lower respiratory tract infection because they were too invasive to carry out in children. Therefore, lower respiratory tract infection may not have been fully excluded in this study. Nevertheless, we believe that this study provides valuable information on IPS in children with HSCT.
In conclusion, we identified acute GVHD (grade II-IV) and prior HSCT as risk factors for IPS in pediatric HSCT recipients. The rapid progression to respiratory failure and high mortality rate following the onset of IPS, despite advances in supportive care, require the development of new preventive measures and treatment modalities. Further preclinical and clinical studies are required to understand the pathogenesis of IPS and improve the prognosis of HSCT recipients.
